--- title: "AI empowers the implementation of new drug regulatory policies, highlighting the value of ChinaAMC SSE STAR Medicine ETF" type: "News" locale: "en" url: "https://longbridge.com/en/news/281622235.md" description: "As of April 3, 2026, the SSE STAR Biology and Medicine Index fell by 2.03%. The performance of constituent stocks varied, with HUIYU PHARMACEUTICAL rising by 4.77%, while HitGen dropped by 5.97%. The ChinaAMC SSE STAR Biology and Medicine ETF fell by 2.26%, with the latest quote at 1.08 yuan. The National Medical Products Administration released a new policy to promote the integration of artificial intelligence and drug regulation. Huaxin Securities pointed out that the pharmaceutical and biotechnology sector will become an emerging pillar industry, with the development model of innovative drugs shifting to a comprehensive drive. The market is focused on the quality of clinical data and long-term value" datetime: "2026-04-03T09:04:11.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/281622235.md) - [en](https://longbridge.com/en/news/281622235.md) - [zh-HK](https://longbridge.com/zh-HK/news/281622235.md) --- # AI empowers the implementation of new drug regulatory policies, highlighting the value of ChinaAMC SSE STAR Medicine ETF As of April 3, 2026, 15:00, the SSE STAR Biology and Medicine Index (000683) fell by 2.03%. Among the constituent stocks, HUIYU PHARMACEUTICAL led the gains with an increase of 4.77%, Yuandong Biotechnology rose by 2.99%, and Haobo Technology increased by 2.36%; HitGen led the declines with a drop of 5.97%, Sino Medical fell by 5.39%, and Novogene decreased by 4.54%. The STAR Biology and Medicine ETF ChinaAMC (588130) fell by 2.26%, with the latest quote at 1.08 yuan. On the news front, the National Medical Products Administration issued the "Implementation Opinions on 'Artificial Intelligence + Drug Supervision'," clearly stating that it will promote the deep integration of artificial intelligence and drug supervision in the future, using intelligent methods to create a higher-level smart drug supervision system. Huaxin Securities pointed out that the 2026 "Two Sessions" will position the pharmaceutical and biotechnology sector as an emerging pillar industry, alongside integrated circuits and aerospace, aiming to build global competitiveness. The development model of innovative drugs has shifted from purely relying on financing to a comprehensive driving approach of product commercialization + overseas R&D licensing + financing. The trend of Chinese innovation going overseas will continue to strengthen in 2026, with the scale of foreign BD transactions in the first quarter already exceeding the total level for the entire year of 2024. Currently, the innovative drug sector has undergone adjustments, and a reasonable return is expected, with the market focusing more on the quality of clinical data and long-term market value. In terms of liquidity, the STAR Biology and Medicine ETF ChinaAMC had a turnover rate of 11.05% during the trading session, with a transaction volume of 6.7593 million yuan, indicating active market trading. Looking at a longer time frame, as of April 3, the average daily transaction volume of the STAR Biology and Medicine ETF ChinaAMC over the past week was 11.5554 million yuan. Data shows that as of March 31, 2026, the top ten weighted stocks in the SSE STAR Biology and Medicine Index were United Imaging Healthcare, BeiGene, Aier Eye Hospital, Bairui Tianheng, Rongchang Bio, Huatai Medical, Junshi Biosciences, Zai Lab, Borui Pharmaceutical, and Yirui Technology, with the top ten weighted stocks accounting for a total of 48.91% ### Related Stocks - [588130.CN](https://longbridge.com/en/quote/588130.CN.md) - [000683.CN](https://longbridge.com/en/quote/000683.CN.md) - [688222.CN](https://longbridge.com/en/quote/688222.CN.md) - [688553.CN](https://longbridge.com/en/quote/688553.CN.md) ## Related News & Research - [Flow Pharma U.S. Patent Application Allowed for Issuance Covering Broad-Spectrum Ebola Therapy](https://longbridge.com/en/news/287076761.md) - [Analyst Reiterates Buy on Microbix, Citing Temporary China Slowdown and Growing Diversified Demand](https://longbridge.com/en/news/286665358.md) - [How network intelligence can help businesses anticipate risks, ensure uptime, and deliver on AI](https://longbridge.com/en/news/286815400.md) - [Jim Cramer Says Nvidia Should Stay Inside China’s AI Boom, Not Walk Away](https://longbridge.com/en/news/286804523.md) - [INSEAD exposes Singapore's immersive learning gap](https://longbridge.com/en/news/286823627.md)